FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative Breast Cancer

The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments.

from latest-news-feed https://ift.tt/2SnBcEi
إرسال تعليق (0)
أحدث أقدم